Perosphere Technologies Adds Dr. Michael Grosso to Advisory Board

DANBURY, Conn.--(BUSINESS WIRE)-- Perosphere Inc. (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today announced Michael A. Grosso, MD, FACS, joins its Advisory Board. As a seasoned pharmaceutical industry executive who helped lead Daiichi Sankyo’s direct oral anticoagulant (DOAC) Phase 3 clinical development, and former academic cardiothoracic surgeon, Dr. Grosso will support Perosphere’s mission to revolutionize patient care through the development and commercialization of innovative diagnostic tools.

“We are thrilled to welcome Dr. Michael Grosso to Perosphere’s Advisory Board,” said Dr. Sasha Bakhru, CEO of Perosphere Technologies. “His knowledge of DOACs and experience in developing therapeutic solutions for patients fully aligns with Perosphere’s mission to offer a complete diagnostic picture of a patient’s coagulation status. His extensive expertise, both in and out of the operating room, and his commitment to cross-functional and cross-cultural collaboration, will ensure that the needs of physicians and patients are fully considered and incorporated into product features and capabilities as we develop and promote the use of Perosphere’s technology.”

Dr. Grosso brings over four decades of healthcare knowledge, including expertise in cardiovascular, hematology, and thrombosis therapeutic areas and in the development of medicines, to his role on the Board. “The technology Perosphere is developing excites me both as a physician and as a leader in clinical development. There is a clear need for more and better point-of-care diagnostics in the coagulation arena, both from a patient care perspective and for use in clinical trials for more timely results. I am honored to have been asked to join the Advisory Board in order to support Perosphere’s great work,” said Dr. Grosso. “Finding ways for physicians to diagnose more accurately and treat patients more confidently have been key goals in my career that dovetail perfectly with Perosphere’s important mission.”

After graduating from The Perelman School of Medicine at the University of Pennsylvania, Dr. Grosso spent 11 years as a cardiothoracic surgeon. He later joined Sanofi as a Cardio/Thrombosis medical advisor before joining Daiichi Sankyo in 2010, where he took on a variety of medical leadership roles. Dr. Grosso is responsible for the pre-clinical, clinical (Phase 1-4), and lifecycle management of the specialty medicine portfolio globally for the orphan/rare genetic disease, neurology, inflammation, ophthalmology, cardiovascular/metabolic, and thrombosis/thrombolysis/hemostasis therapeutic areas.

About Perosphere Technologies

Perosphere Technologies is changing the way decisions are made for patients at risk of bleeding. A private medical technologies company, Perosphere is focused on development and commercialization of its novel PoC (point-of-care) Coagulometer, which informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. It is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including DOACs. The fast diagnosis and related appropriate treatment decisions the PoC Coagulometer enables will help establish a new standard of care in hospitals, at the point-of-care, for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes. The PoC Coagulometer has a CE Mark in the EU but is not yet cleared in the US.

For further information, contact us at info@perospheretech.com or +1 (475) 218-4600.

www.perospheretech.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240520203580/en/